While Ireland is globally celebrated as a premier biopharmaceutical manufacturing powerhouse—hosting manufacturing sites for nine of the world's top ten pharmaceutical corporations and employing tens of thousands of people in advanced biomanufacturing—a stark and troubling paradox lies at the heart of the country's healthcare system. When it comes to patient access to innovative, life-saving medicines and specialized "orphan" drugs for rare diseases, Ireland ranks among the slowest and most restrictive nations in Western Europe. The latest industry benchmarks have sparked intense debate among patient advocates, industry bodies, and policymakers, leading to mounting calls for a comprehensive, structural overhaul of the country's drug pricing, appraisal, and reimbursement systems.
According to the newly released 2025 European Federation of Pharmaceutical Industries and Associations (EFPIA) Patients W.A.I.T. (Waiting to Access Innovative Therapies) Indicator, published in 2026, the average time it takes for an Irish patient to gain access to a new medicine after it has received marketing authorization from the European Medicines Agency (EMA) has deteriorated to a staggering 801 days. This means Irish patients must wait over two years to receive cutting-edge therapies that are already routinely available in other European states. To put this in perspective, the average wait time across all European Union member states is 614 days, while patients in Germany enjoy access within an average of 127 days. Ireland's lag is not just a statistical outlier; it is a clinical bottleneck that directly impacts patient outcomes and survival rates.
The Crisis of Orphan Medicine Reimbursement
The access deficit is particularly severe in the realm of rare diseases and specialized orphan drugs. A rare disease is defined in the EU as a condition affecting fewer than 5 in 10,000 people. Collectively, however, rare diseases affect over 300,000 people in Ireland alone. Because these conditions are often chronic, progressive, and life-threatening, timely access to orphan drugs—medicines specifically developed to treat rare conditions—is a matter of life and death.
Currently, Ireland’s public reimbursement system only covers a small fraction of EMA-authorized orphan medicines. Data from recent access reports indicate that only about 27% of orphan drugs approved by the EMA between 2020 and 2023 are publicly funded and reimbursed in Ireland. In contrast, Germany funds over 90% of these specialized therapies, and other comparable small nations like Denmark and Austria reimburse over 50%. The Irish Pharmaceutical Healthcare Association (IPHA) and advocacy groups like Rare Diseases Ireland (RDI) have repeatedly warned that the current system is failing rare disease patients, leaving families in the agonizing position of knowing a treatment exists but being unable to access it through the public healthcare system.
Bottlenecks in the HTA Process: The Role of the NCPE
The primary bottleneck in Ireland's reimbursement pathway is the health technology assessment (HTA) process. In Ireland, once a pharmaceutical company submits a new medicine for reimbursement, it undergoes a rigorous pharmacoeconomic evaluation conducted by the National Centre for Pharmacoeconomics (NCPE). The NCPE is tasked with assessing whether a drug provides sufficient clinical value relative to its cost, ensuring that the Health Service Executive (HSE) allocates public funds responsibly.
However, the NCPE's assessment methodology is widely criticized for being rigid and ill-suited for rare disease therapies. Because orphan drugs are designed for tiny patient populations, their clinical trials naturally feature small sample sizes, making it difficult for manufacturers to provide the massive, long-term randomized control trial data that the NCPE typically demands. This leads to a cycle of repeated evidence requests, lengthy appeals, and protracted price negotiations between the HSE and manufacturers, pushing approval timelines out by hundreds of days. Additionally, unlike other EU nations, Ireland lacks a formal, centralized "early access" or "compassionate use" framework, leaving patients without any interim access to drugs undergoing appraisal.
Proposed Reforms and the National Rare Disease Strategy
Facing growing political pressure and public outcry, the Irish government has initiated several key reform efforts. The Department of Health has launched the National Rare Disease Strategy (2025–2030), which aims to provide a comprehensive, patient-centered framework to accelerate diagnoses, expand newborn screening, and streamline access to specialized care and therapies.
Crucially, the government has committed to an "end-to-end" review of the entire drug approval and reimbursement system. The review is focused on identifying specific operational bottlenecks within the NCPE and HSE, and establishing clearer, more transparent timelines. Under the latest framework agreements on pricing and supply, the state has set a progressive target to transition toward a statutory 180-day reimbursement timeline by the first quarter of 2029. This target is aligned with the EU's Transparency Directive, which legally mandates a 180-day limit for national reimbursement decisions—a standard that Ireland has historically struggled to meet.
The EU Presidency: A Catalyst for Action
Ireland's assumption of the rotating Presidency of the Council of the European Union on July 1, 2026, presents a unique and timely opportunity. As Minister for Health Jennifer Carroll MacNeill leads negotiations on the wider EU Pharmaceutical Package and the Biotech Act, Ireland can leverage its presidency to drive systemic changes at both the domestic and European levels.
By championing reforms that simplify clinical trial rules and standardize HTA criteria across EU member states, Ireland can help create a more agile European regulatory environment. Domestically, the government can use this period of heightened focus to accelerate its own system reviews. Reforming Ireland's drug approval system is not simply an administrative task; it is a moral imperative. By modernizing the NCPE's HTA models, investing in dedicated rare disease funding pools, and implementing the 180-day target, Ireland can bridge the 801-day access gap and ensure that its world-class pharmaceutical manufacturing sector is matched by a world-class patient access system.
